Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 802-805    DOI: 10.31083/j.ejgo.2020.05.5155
Case Report Previous articles | Next articles
Endocervical adenocarcinoma in situ with ovarian metastasis: a case report
Špela Smrkolj1, 2, *(), Snježana Frković Grazio3, Renata Košir Pogačnik1
1Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, Ljubljana, Slovenia
2Faculty of Medicine; University of Ljubljana, Ljubljana, Slovenia
3Division of Gynecology and Obstetrics, Department of Gynecologic Pathology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Download:  PDF(457KB)  ( 126 ) Full text   ( 12 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Ovarian metastases, which may simulate primary ovarian neoplasms, can occur in advanced stage primary cervical adenocarcinoma (AC). However, such tumors are very rarely observed in cases of endocervical adenocarcinoma in situ (AIS) with early or even no obvious signs of tumor invasion. Case: We present a case of ovarian metastasis occurring in a 37-year-old triparous premenopausal woman with a diagnosed case of endocervical AIS. The patient presented with a rapidly growing and painful abdominal mass 22 months after a cold knife cone biopsy and 19 months after a simple extrafascial hysterectomy. She was subsequently treated with a combination of surgery and chemotherapy and is currently free of disease seven years after the initial diagnosis of endocervical AIS lacking unequivocally recognizable stromal invasion. Conclusion: Endocervical AIS with early or even no obvious detectable invasion may spread to the ovaries, but this situation is exceptionally rare. We propose that, in such cases, ovary sparing surgery is justifiable for initial treatment. Medical care strategies for patients affected by rare diseases largely depend on experience gained from reported cases in published literature, this is what compelled us to report this particular case.
Key words:  Ovarian metastasis      Adenocarcinoma in situ      Uterine cervix     
Submitted:  02 February 2019      Accepted:  09 April 2019      Published:  15 October 2020     
*Corresponding Author(s):  spela.smrkolj@mf.uni-lj.si; spsmrkolj@gmail.com (ŠPELA SMRKOLJ)   

Cite this article: 

Špela Smrkolj, Snježana Frković Grazio, Renata Košir Pogačnik. Endocervical adenocarcinoma in situ with ovarian metastasis: a case report. European Journal of Gynaecological Oncology, 2020, 41(5): 802-805.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5155     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/802

[1] Qihua Yi, Lin Chen, Sijing Chen, Ying Zheng. Criteria for predicting ovarian metastasis in early-stage cervical adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 726-731.
[2] N. Kosaka, K. Hasegawa, K. Kiuchi, S. Ochiai, E. Motegi, I. Fukasawa. Two cases of recurrent small-cell carcinoma of the uterine cervix treated with amrubicin as salvage chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1100-1103.
[3] S. Rahatli, H. Akilli, N. Haberal, O. Altundag, A. Haberal, A. Ayhan. Surgical management and outcomes of metastatic tumors to the ovaries[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 820-824.
[4] Z. Protrka, A. Dimitrijevic, N. Jovic, T. Kastratovic, J. Djuric, J. Nedovic, S. Zivanovic, A. Vujic, S.M. Drakulic, N. Djonovic, P. Arsenijevic. Expression analysis of the Beclin-1 in premalignant and malignant tissues of the uterine cervix[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 915-920.
[5] G. Giordano, A. Pezzuto, E.M. Silini. Ovarian metastasis from renal clear cell carcinoma: a case report with an intraoperative, immunohistochemical study, and a review of the literature[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 1022-1027.
[6] M. Degirmenci, G. Diniz, D. Solakoglu Kahraman, S. Sayhan, P. Oksuz, D. Ayaz, T. Karadeniz, Z. Altin, M. Sanci. Evaluation of the Caveolin-1 expressions in uterine cervical carcinomas[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 785-789.
[7] G.M. Makris, C. Chrelias, A. Papanota, M.J. Battista, N. Papantoniou. Ovarian tumors: Should the cervix be examined first?[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 462-464.
[8] S. Oliveira Calil de Paula, M.C. de Assis Brito Alves, J.O. de Almeida Falcão Junior, C.L. Soares Laranjeira, M. Salvador Géo. Importance of differential diagnosis post-treatment of adenocarcinoma of the uterine cervix: a case report of sarcoidosis[J]. European Journal of Gynaecological Oncology, 2016, 37(5): 714-716.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .